RVNC
$25.35
Revance Therapeutics
($.82)
(3.13%)
RVNC
Earnings Whisper ®
N/A
1st Quarter March 2021
Consensus:  ($1.04)
Revenue:  N/A
Monday
May 24
4:05 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when RVNC reports earnings?
Beat
Meet
Miss

Where is RVNC's stock price going from here?
Up
Flat
Down
Stock chart of RVNC
Analysts
Summary of analysts' recommendations for RVNC
Score
Grade
Pivots
Resistance
$28.00
$27.38
$26.78

$26.16

Support
$25.56
$24.94
$24.34
Tweet
Growth
Description
Revance is a Silicon Valley-based biotechnology company. The company is developing a portfolio of products for aesthetic medicine and underserved therapeutic specialties, including dermatology and neurology. Revance's science is based upon a proprietary TransMTS? peptide technology, which when combined with active drug molecules, may help address current unmet needs. Revance's initial focus is on developing daxibotulinumtoxinA, the company's highly purified botulinum toxin, for a broad spectrum of aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders. The company's lead drug candidate, DaxibotulinumtoxinA for Injection (RT002), is currently in development for the treatment of glabellar lines and cervical dystonia and has the potential to be the first long-acting neurotoxin. The company holds worldwide rights for all indications of RT002 injectable and RT001 topical and the pharmaceutical uses of the TransMTS technology platform.
Peers
InterCeptVertex PharmaceuticalsRegeneron PharmaceuticalsBioMarin PharmaceuticalBristol-Myers SquibbPfizerZoetisMerck & Co.Johnson & JohnsonUltragenyx Pharmaceutical